HTSUFOTC Markets OTCPK
Hisamitsu Pharmaceutical Co., Inc.
$29.00
ListedSep 23, 2010
SectorHealthcare
IndustryDrug Manufacturers — Specialty & Generic
CountryJapan
Employees-
State-| CityTosu| AddressTashirodaikan-machi 408| Phone81 3 5293 1720
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asia, the United States, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan. As of February 19, 2026, Hisamitsu Pharmaceutical Co., Inc. operates as a subsidiary of Taiyo Kosan Co., Ltd.

Key Indicators

Key financial and dividend metrics for this stock.

?
P/E Ratio
16.8
?
Div. Rate
$0.61
?
Div. Yield
2.11%
?
Payout Ratio
32.66%
?
Max Consec. Div. Years
15 years
?
Longest Consec. Div.
15 years
?
Div. Coverage
100%
?
Div. Stability Rate
0.10
?
Div. Growth Rate
100.00%
?
Score
97

Dividend History

Historical dividend payments by ex-dividend date.

Aug 28, 2025
$ 0.3755
Feb 27, 2025
$ 0.2817
Aug 29, 2024
$ 0.2817
Feb 28, 2024
$ 0.2660
Aug 30, 2023
$ 0.2660
Feb 27, 2023
$ 0.2644
Aug 30, 2022
$ 0.2644
Feb 25, 2022
$ 0.2629
Aug 30, 2021
$ 0.2629
Feb 25, 2021
$ 0.2613
Aug 28, 2020
$ 0.2613
Feb 27, 2020
$ 0.2598
Aug 29, 2019
$ 0.2598
Feb 26, 2019
$ 0.2582
Feb 26, 2018
$ 0.2566
Feb 24, 2017
$ 0.2566
Aug 29, 2016
$ 0.2535
Feb 25, 2016
$ 0.2566
Aug 27, 2015
$ 0.2504
Feb 25, 2015
$ 0.2660
Aug 27, 2014
$ 0.2347
Feb 26, 2014
$ 0.2504
Aug 28, 2013
$ 0.2191
Feb 26, 2013
$ 0.2191
Aug 29, 2012
$ 0.2191
Aug 29, 2011
$ 0.2191

Peer Companies

Other stocks in the same sector.

The app download will be available in the next version. Stay tuned!